Research ArticleOriginal Article
Open Access

Disease-specific quality of life in patients with diabetic neuropathy

Mushabab Alghamdi, Lukman F. Owolabi, Bappa Adamu, Magaji G. Taura, Abubakar Jibo, Mohammed Almansour, Saeed N. Alaklabi, Mohammed A. Alghamdi, Isa A. Imam, Reda Abdelrazak, Ahmad Rafaat and Muktar H. Aliyu
Saudi Medical Journal April 2022, 43 (4) 408-417; DOI: https://doi.org/10.15537/smj.2022.43.4.20210861

References

  1. 1.↵
    1. Guariguata L,
    2. Whiting DR,
    3. Hambleton I,
    4. Beagley J,
    5. Linnenkamp U,
    6. Shaw JE.
    Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137–149.
  2. 2.↵
    1. Papadopoulos AA,
    2. Kontodimopoulos N,
    3. Frydas A,
    4. Ikonomakis E,
    5. Niakas D.
    Predictors of health-related quality of life in type II diabetic patients in Greece. BMC Public Health 2007; 7: 186.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Pop-Busui R,
    2. Boulton AJM,
    3. Feldman EL,
    4. Bril V,
    5. Freeman R,
    6. Malik RA, et al.
    Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136–154.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Boulton AJM,
    2. Vileikyte L,
    3. Ragnarson-Tennvall G,
    4. Apelqvist J.
    The global burden of diabetic foot disease. Lancet Lond Engl 2005; 366: 1719–1724.
    OpenUrl
  5. 5.↵
    1. Smith SC,
    2. Lamping DL,
    3. Maclaine GDH.
    Measuring health-related quality of life in diabetic peripheral neuropathy: a systematic review. Diabetes Res Clin Pract 2012; 96: 261–170.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Fitzpatrick R,
    2. Fletcher A,
    3. Gore S,
    4. Jones D,
    5. Spiegelhalter D,
    6. Cox D.
    Quality of life measures in health care. I: Applications and issues in assessment. BMJ 1992; 305: 1074–1077.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Wändell PE.
    Quality of life of patients with diabetes mellitus. An overview of research in primary health care in the Nordic countries. Scand J Prim Health Care 2005; 23: 68–74.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Dermanovic Dobrota V,
    2. Hrabac P,
    3. Skegro D,
    4. Smiljanic R,
    5. Dobrota S,
    6. Prkacin I, et al.
    The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes 2014; 12: 171.
    OpenUrl
  9. 9.↵
    1. Van Acker K,
    2. Bouhassira D,
    3. De Bacquer D,
    4. Weiss S,
    5. Matthys K,
    6. Raemen H, et al.
    Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206–213.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Sultan Intessar (last), Abozed Olfat, Alkhouly Nashwa, Osman Eman Naguib, Alduhailib Hassan, Alotaibi, et al. Health-related quality of life (Hrqol) in type 2 diabetes patients with painful neuropathy before and after 6 weeks pregabalin therapy. Int J Life Sci Pharma Res 2019; 9: 65–72.
  11. 11.
    1. Elizabeth A. Stuart
    . Matching methods for causal inference: A review and a look forward. Stat Sci 2010; 25: 1–21.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Herman WH,
    2. Pop-Busui R,
    3. Braffett BH,
    4. Martin CL,
    5. Cleary PA,
    6. Albers JW, et al.
    Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the diabetes control and complications trial/epidemiology of diabetes interventions and complications. Diabet Med J Br Diabet Assoc 2012; 29: 937–944.
    OpenUrl
  13. 13.↵
    1. Boyd A,
    2. Casselini C,
    3. Vinik E,
    4. Vinik A.
    Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol 2011; 5: 714–722.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Vinik EJ,
    2. Hayes RP,
    3. Oglesby A,
    4. Bastyr E,
    5. Barlow P,
    6. Ford-Molvik SL, et al.
    The development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 2005; 7: 497–508.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Brown JJ,
    2. Kimberly G. Baskette,
    3. Sheri R Colberg,
    4. Shane Pribesh,, Aaron I.
    Vinik. A comparison of neuropathy quality of life tools: Norfolk QOL-DN, PN-QOL-97, and NeuroQOL-28. Med Res Arch 2021; 9: 11.
    OpenUrl
  16. 16.
    1. Alberti KG,
    2. Zimmet PZ. Definition
    , diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
  17. 17.↵
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Akpa OM,
    2. Okekunle AP,
    3. Ovbiagele B,
    4. Sarfo FS,
    5. Akinyemi RO,
    6. Akpalu A, et al.
    Factors associated with hypertension among stroke-free indigenous Africans: Findings from the SIREN study. J Clin Hypertens (Greenwich) 2021; 23: 773–784.
    OpenUrl
  19. 19.↵
    1. O’Donnell M,
    2. Xavier D,
    3. Diener C,
    4. Sacco R,
    5. Lisheng L,
    6. Zhang H,
    et al. Rationale and design of INTERSTROKE: a global case-control study of risk factors for stroke. Neuroepidemiology 2010; 35: 36–44.
  20. 20.↵
    World Health Organization. Obesity and overweight. [Updated 2017; cited 2021 Aug 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
  21. 21.↵
    1. Benbow SJ,
    2. Wallymahmed ME,
    3. MacFarlane IA.
    Diabetic peripheral neuropathy and quality of life. QJM 1998; 91: 733–737.
  22. 22.↵
    1. Degu H,
    2. Wondimagegnehu A,
    3. Yifru YM,
    4. Belachew A.
    Is health related quality of life influenced by diabetic neuropathic pain among type II diabetes mellitus patients in Ethiopia? PLOS ONE 2019; 14: e0211449.
    OpenUrl
  23. 23.
    1. Gilron I,
    2. Baron R,
    3. Jensen T.
    Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc 2015; 90: 532–545.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Ware JE,
    2. Sherbourne CD.
    The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–483.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.
    1. van Schie CHM.
    Neuropathy: mobility and quality of life. Diabetes Metab Res Rev 2008; 24: S45–S51.
    OpenUrlCrossRefPubMed
  26. 26.
    1. Ylitalo KR,
    2. Herman WH,
    3. Harlow SD.
    Performance-based Physical Functioning and Peripheral Neuropathy in a Population-based Cohort of Women at Midlife. Am J Epidemiol 2013; 177: 810–817.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Olmez N,
    2. Degirmenci Y,
    3. Kececi H.
    Effects of Pain and Disability on Quality of Life in Patients with Diabetic Polyneuropathy. Neurosci Med 2015; 6: 98–106.
    OpenUrl
  28. 28.↵
    1. Manca A,
    2. Eldabe S,
    3. Buchser E,
    4. Kumar K,
    5. Taylor RS.
    Relationship between health-related quality of life, pain, and functional disability in neuropathic pain patients with failed back surgery syndrome. Value Health 2010; 13: 95–102.
    OpenUrlPubMed
  29. 29.↵
    1. Genga E,
    2. Otieno CF,
    3. Ogola EN,
    4. Maritim MC.
    Assessment of the perceived quality of life of non-insulin dependent diabetic patients attending the diabetes clinic in Kenyatta National Hospital. Diabetes Res Clin Pract 2014; 103: S36.
    OpenUrl
  30. 30.↵
    1. Pichon-Riviere A,
    2. Irazola V,
    3. Beratarrechea A,
    4. Alcaraz A,
    5. Carrara C.
    Quality of life in type 2 diabetes mellitus patients requiring insulin treatment in Buenos Aires, Argentina: a cross-sectional study. Int J Health Policy Manag 2015; 4: 475–480.
    OpenUrl
  31. 31.
    1. Van der Does FE,
    2. De Neeling JN,
    3. Snoek FJ,
    4. Kostense PJ,
    5. Grootenhuis PA,
    6. Bouter LM, et al.
    Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996; 19: 204–210.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    1. van der Does FE,
    2. de Neeling JN,
    3. Snoek FJ,
    4. Grootenhuis PA,
    5. Kostense PJ,
    6. Bouter LM, et al.
    Randomized study of two different target levels of glycemic control within the acceptable range in type 2 diabetes. Effects on well-being at 1 year. Diabetes Care 1998; 21: 2085–2093.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Kleefstra N,
    2. Ubink-Veltmaat LJ,
    3. Houweling ST,
    4. Groenier KH,
    5. Meyboom-de Jong B,
    6. Bilo HJG.
    Cross-sectional relationship between glycaemic control, hyperglycaemic symptoms and quality of life in type 2 diabetes (ZODIAC-2). Neth J Med 2005; 63: 215–221.
    OpenUrlPubMed
  34. 34.
    1. Goddijn PP,
    2. Bilo HJ,
    3. Feskens EJ,
    4. Groeniert KH,
    5. van der Zee KI,
    6. Meyboom-de Jong B.
    Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control. Diabet Med 1999; 16: 23–30.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care 1999; 22: 1125–1136.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Hussein A,
    2. Nour G,
    3. Sidig A,
    4. El-adil O,
    5. Hamad A,
    6. Malkaldar M, et al.
    The prevalence of neurological complications among adult Sudanese diabetic patients. undefined. [Updated 2009; cited 2021 Aug 28]. Available from: https://www.semanticscholar.org/paper/The-prevalence-of-neurological-complications-among-Hussein-Nour/59c0d878d6da93c100a78a8cd11459bbe1dbbcab
  37. 37.↵
    1. Jensen MP,
    2. Chodroff MJ,
    3. Dworkin RH.
    The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007; 68: 1178–1182.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords